Rothia, a microbiota component of warthogs, has immunostimulatory properties in vitro and in vivo.

1) Ensuring the viability of the proposal by unmasking the potential market of our inventions and designing the optimal strategy for protecting the intellectual property of the discoveries.
2) Providing enough scientific evidence for optimal technological transfer including the full in vitro characterization of Rothia, optimizing its use as an ASF vaccine adjuvant, exploring its use as a universal vaccine adjuvant and/or immunostimulatory molecule in vivo, and assessing if these immunostimulatory properties are found also in isolates belonging to Rothia genus from domestic pigs.
3) Designing a business plan a la carte for the technological transfer of the fact of the invention that IRTA holds long-term agreements with most national and multinational companies from the agronomic sector favors the possibility of mutually beneficial alliance from the beginning for this adventure.